| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5196444 (Pediatric) | ANI PHARMS | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
Dec, 2012
(11 years ago) | |
| US5534534 | ANI PHARMS | Pharmaceutical compositions for oral use and method of preparing them |
Jul, 2013
(10 years ago) | |
|
US5534534 (Pediatric) | ANI PHARMS | Pharmaceutical compositions for oral use and method of preparing them |
Jan, 2014
(10 years ago) | |
| US5958961 | ANI PHARMS | Pharmaceutical composition for angiotensin II-mediated diseases |
Jun, 2014
(9 years ago) | |
| US5721263 | ANI PHARMS | Pharmaceutical composition for angiotensin II-mediated diseases |
Feb, 2015
(9 years ago) | |
Atacand Hct is owned by Ani Pharms.
Atacand Hct contains Candesartan Cilexetil; Hydrochlorothiazide.
Atacand Hct has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Atacand Hct are:
- US5196444*PED
- US5534534
- US5534534*PED
- US5958961
- US5721263
Atacand Hct was authorised for market use on 05 September, 2000.
Atacand Hct is available in tablet;oral dosage forms.
Atacand Hct can be used as treatment of hypertension.
The generics of Atacand Hct are possible to be released after 24 February, 2015.
Drugs and Companies using CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE ingredient
Market Authorisation Date: 05 September, 2000
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
ATACAND HCT family patents
